Martinez-Thompson, JM and Snyder, MR and Ettore, M and McKeon, A and Pittock, SJ and Roforth, MM and Mandrekar, J and Mauermann, ML and Taylor, BV and Dyck, PJB and Windebank, AJ and Klein, CJ, Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM, Muscle and Nerve, 57, (6) pp. 1000-1005. ISSN 0148-639X (2018) [Refereed Article]
Copyright 2017 Wiley Periodicals, Inc.
Methods: We reviewed 35 patients seropositive for GM1 (monosialo-asialo [immunoglobulin M, IgM; immunoglobulin G, IgG]) and/or GD1b (disialo [IgG, IgM]) autoantibodies having MMN, classic CIDP, or MADSAM. Immune-treatment responsiveness and clinical course was compared with antibody negative disease controls.
Results: Seventy-nine percent of seropositives with an initial diagnosis of MMN were immunotherapy responsive compared with 46% of seronegatives (P = 0.045). Eight ganglioside antibody positive MMN patients of 19 (42%) developed sensory findings consistent with MADSAM compared with 3 of 41 (7%) seronegative MMN patients (P = 0.003). MMN and MADSAM patients with ganglioside antibody positivity had more sustained treatment responses (P = 0.03).
Discussion: Patients initially diagnosed with MMN seropositive for diverse GM1 autoantibodies appear more likely to have sustained treatment response and evolution to MADSAM.
|Item Type:||Refereed Article|
|Keywords:||CIDP, MADSAM, MMN, gangliosides|
|Research Division:||Biomedical and Clinical Sciences|
|Research Field:||Central nervous system|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Taylor, BV (Professor Bruce Taylor)|
|Web of Science® Times Cited:||3|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page